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There is growing interest in gene transfer into various tissues of the eye since there are many ocular disorders which may be amenable to gene therapy. 1 Of these, there is particular interest in developing gene therapy for inherited retinal degenerations, some of which are due to single gene defects in photoreceptor-specific genes. These disorders may ultimately be treated by gene replacement strategies which require gene transfer to photoreceptors or by strategies which prevent these cells entering the apoptotic pathway. The latter might be achieved, for instance, by the delivery of genes encoding neurotrophic growth factors to the adjacent retinal pigment epithelium (RPE) cells or to cells in the anterior chamber. A number of vectors, including those based on herpes simplex virus (HSV), 2 lentivirus 3 and adeno-associated virus (AAV) [4] [5] [6] [7] have been used for ocular gene transfer but, to date, the most widely reported system is that based on adenoviral (AV) vectors. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Studies in either the rabbit or more often the mouse, using these AV vectors carrying a lacZ reporter gene, have demonstrated that cells in the anterior segment, including the corneal endothelium, iris pigment epithelium, ciliary body, trabecular meshwork and Schlemms canal, may be efficiently transduced by intra-cameral injection. Subretinal injection is required for efficient targeting of the RPE and also results in the transduction of a small proportion of photoreceptors.
Host immune responses to vector and transgene currently present a general problem for long-term gene delivery. There has been particular concern about the immunogenicity of AV vectors. The current generation of AV vectors have deletions in their E1 and E3 regions but are, nevertheless, able to produce viral proteins. Immune responses against vector-encoded proteins have been demonstrated after in vivo transduction of a variety of tissues in humans and mice. In the mouse this has been demonstrated in the heart and lung, 20 muscle 21, 22 and liver. 23 Neutralising antibodies to adenoviral capsid proteins prevent effective re-administration of the vector, and cytotoxic T lymphocytes (CTLs) mediate the destruction of transduced cells, thus reducing the level of transgene expression over time. [24] [25] [26] Immune responses to the transgene have also been demonstrated, although it is possible that there is some vector-dependent or tissuedependent variation in the immunogenicity of the transgene. 22 We have previously demonstrated that an immune response also limits the duration of AV-mediated reporter gene expression in both the anterior and posterior segment of the eye. 27 We found no evidence to support an earlier report which suggested that the retina is normally immune privileged with respect to adenoviral vectors. 28 Although the level of expression declined in T cell-deficient nude mice, possibly because of viral promoter inactivation, the duration of expression was considerably longer than in congenic immune-competent a b 
u. AdRL in PBS). The results indicate transduction of RPE cells by either one type of virus (a) or by both (b). The difference in intensity of X-gal and DAB staining in (a) and (b) probably reflects a difference in viral copy number.
Control uninjected eyes showed no X-gal staining and minimal background DAB staining which was confined to the sclera. Eyes were enucleated and incubated in X-gal overnight as previously described. 4 Immunohistochemistry using an antihuman Ig antibody (Sigma, Poole, UK) was then performed on 5 m paraffin sections and counterstained with nuclear fast red (×100).
animals indicating that the primary reason for the decline in expression is a cytotoxic immune response. Inflammatory cells may be observed in the vitreous after anterior chamber injection of adenoviral vectors and in the retina after subretinal injection. 14, 27 It appears therefore that 'immune privilege' associated particularly with transplants into the anterior chamber, 29 but more recently also to the space, 30 does not apply to cells infected with virus by intra-ocular injection. This is perhaps not surprising since virus injected into the anterior segment drains out into the venous blood stream and injection of virus into the posterior segment disrupts the blood-retinal barrier. Li et al, 9 however, observed scattered reporter gene expression 6 weeks after subretinal injection of neonatal CB-17 mice, presumably by circumventing the developing immune system.
The destruction of transduced cells is particularly serious when the cells are post-mitotic, and are therefore not replaced, as is the case with photoreceptors. Although it may be possible to use vectors which are less immunogenic, in those instances where the transgene encodes an antigenic protein, this problem will remain. General immune suppression may allow long-term gene delivery in animal models, but would present unacceptable risks to patient health. It is therefore important to develop alternative strategies for modulating the immune response such as tolerisation of recipients to vector and transgene products, or induction of local immune suppression. The latter is the subject of this study.
Initiation of a T cell-mediated immune response requires a number of signals from antigen presenting cells (APC). The APC presents antigen as a short peptide in association with major histocompatibility molecules to a T cell receptor. However, in order to elicit a productive T cell response, costimulatory signals are required. These are provided by B7-1 (CD80) and B7-2 (CD86) ligands present on APC, which bind to CD28 and CTLA4 (CD152) receptors on T cells. 31 Presentation of antigens without the costimulatory signals produces T cell anergy. General immune suppression may be induced in mice by inhibiting the CD28-B7 costimulatory signals by systemic administration of a recombinant chimeric protein, CTLA4-Ig, which consists of an immunoglobulin fused to CTLA4. 32 Kay et al 33 have demonstrated, in mice, that administration of muCTLA4-Ig, consisting of murine immunoglobulin C␥2a fused to murine CTLA4, extends the duration of adenovirus-mediated gene expression in the liver. They have also recently demonstrated that constitutive expression of murine CTLA4Ig from the viral vector also prolongs transgene expression. 34 In this article we have examined whether local virally produced CTLA4-Ig is also capable of extending the duration of AV-mediated expression in the eye by preventing local T cell activation.
An E1-deleted replication-deficient adenoviral vector, AdCTLA, was used which encodes a mouse CTLA4 human Fc␥1 fusion protein driven by an RSV promoter. 19 This protein has previously been shown to be functionally active, as determined by binding to B7.1 expressing transfectants. 19 A series of BALB/c mice was subretinally injected with a mixture of AdCTLA and AdRL, an E1-deleted adenoviral vector containing a lacZ reporter gene also driven by an RSV promoter. The surgical procedure was carried out as previously described. 4 Eyes were enucleated at 16 days, 21 days and 62 days after injection and incubated in X-gal. Six eyes were also embedded in paraffin wax and sectioned. Subsequent immunohistochemistry using a human Ig-specific antibody against the Ig portion of the CTLA4-Ig molecule revealed that the majority of transduced RPE cells had been infected by both types of virus. However, some RPE cells were positive only for either ␤ galactosidase or CTLA4-Ig indicating transduction by only one of the two viruses in the injected mixture (Figure 1) . A similar pat- tern was observed in all eyes examined. Co-injection of AdCTLA and AdRL extended the duration of lacZ expression in the retina compared with injection of only AdRL (Figure 2) . In order to avoid subjective assessments of the level of expression, the data in Figure 2 are presented as either the presence or absence of X-gal staining. Three weeks after injection, less than half the number of eyes from control mice injected with only AdRL were positively stained with X-gal compared with eyes from mice that were co-injected. Although there was some variation in the level of expression within each group (Figure 3) , at this time-point positive eyes from the co- 35 This indicates that the dose of virus used in this study is too low to induce general immune suppression. The local T cell suppression we have observed as a result of injecting adenovirus expressing CTLA4-Ig appeared to be effective for only a short time. By 9 weeks after injection there was little difference compared with controls. One explanation may be that the CTLA4-Ig protein produced by the recombinant adenovirus was itself immunogenic. The Ig portion of the protein was derived from human sequence. Using ELISA, we detected circulating antibodies to human Ig in the serum of AdCTLA injected, but not in AdRL injected animals (data not shown). This may have rapidly reduced the effectiveness of local suppression by reducing the level of functional CTLA4-Ig which may have eventually also allowed some T cell-mediated destruction of CTLA4-Ig producing cells resulting in even further reduced levels of secreted CTLA4-Ig. It is unlikely that the duration of lacZ expression would have been significantly extended if CTLA4-Ig had been expressed from the same vector since most of the transduced RPE cells were co-infected with both types of virus.
In summary, we have demonstrated that local expression of CTLA4-Ig is capable of extending the duration of virally mediated gene expression. However, the effectiveness of this strategy might be improved by the application of a viral vector carrying a CTLA4-Ig gene which is entirely mouse in origin. This approach may also be useful for other situations in which local immune suppression may be desirable; for example, to reduce T cell activation in target tissues in individuals who are susceptible to autoimmune disease and in transplanted organs which are prone to rejection.
